Forte Biosciences FBRX 深 沪

Argenx Secures Promising Autoimmune Drug In Forte Biosciences Takeover

Argenx is acquiring Forte Biosciences in a $2.2 billion all-cash deal. The $77 per share buyout expands its autoimmune drug portfolio.

07-28 00:16

Gold Gains Over 1%; PepsiCo Shares Fall After Q2 Results

U.S. stocks higher, Dow gains over 150 points. NASDAQ up 0.84%, S&P 500 up 0.60%. Tech shares jump 1.3%, communication services down 1.7%. PepsiCo falls 5% on earnings miss. VRAX up 260%, FBRX up 42%, RKTO up 36%. AFJK drops 47%, GLOO down 19%, RXT down 23%. Oil down 0.9%, gold up 1.3%, silver up 3.6%, copper up 2.6%. European markets mostly higher, Asian markets mixed. U.S. jobless claims decline to 215,000.

07-10 00:02

Forte Biosciences Reports Results From FB102 Double-Blind Placebo-Controlled Phase 1b Study In Vitiligo

Statistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102

07-09 20:08

Forte Biosciences Reveals Proposed Public Offering; No Size Disclosed

Forte Biosciences, Inc. (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced that it has commenced an underwritten public offering of shares of

04-09 04:03

FibroBiologics Closes Third $5 Million Tranche of $25 Million Financing

2025-06-16 20:35

12 Health Care Stocks Moving In Thursday's Intraday Session

Gainers Pasithea Therapeutics (NASDAQ:KTTA) stock moved upwards by 66.4% to $6...

2024-09-27 00:31